67 Monroe Avenue, Pittsford, NY 14534 / 9am - 4pm M-F
Back to Blog

Big Cap Pharma Stocks Still Look Like a Good Place to Invest Among U.S. Equities

Why? Mid-single digit top line growth, double-digit bottom line, with no help from drug pricing, but a growing pipeline of new product launches. Healthcare reform continues to slip to the back burners of the Washington, D.C. agenda as other items take priority. The sector has many great balance sheets with above average dividend yields. As the chart shows, the U.S. pharma multiples are trading at discounts not seen in over a decade. 

This material is for informational purposes only, it is not intended to serve as a substitute for personalized investment advice or as a recommendation or solicitation of any particular security, strategy, or investment product. Opinions expressed herein are based on economic and market conditions at the time this material was written, and do not necessarily reflect the views of LVW Advisors. Economies and markets fluctuate. Actual economic or market events may turn out differently than anticipated. Facts presented have been obtained from sources believed to be reliable.

Ready to get serious about your investments?

LVW Advisors (“LVW”) is a federally registered investment adviser under the Investment Advisers Act of 1940. Registration as an investment adviser does not constitute an endorsement of LVW by the SEC nor does it indicate that LVW has attained a particular level of skill or ability. This website https://lvwadvisors.com is owned and operated by LVW Advisors. LVW offers investment advisory services. All content available on this website is general in nature, not directed or tailored to any particular person, and is for informational purposes only. Neither the website or any of its content is offered as investment advice and should not be deemed as investment advice or a recommendation to purchase or sell any specific security. Neither this website nor its contents should be construed as legal, tax, or other advice. Individuals should consult with their own tax or legal advisers before entering into any advisory contract.